Key result
A 71-year-old patient with Carney complex achieved biochemical control of acromegaly using Pegvisomant after transsphenoidal surgery for a GH-secreting macroadenoma and removal of an atrial myxoma.
Case Report (n=1)
No
This case highlights the importance of recognizing acromegaly and cardiac myxoma as potential manifestations of Carney Complex to ensure timely diagnosis and appropriate long-term multidisciplinary management.
Supports Carney Complex consideration in acromegaly with myxoma; leaves open optimal long-term surveillance protocols.
Introduction: The Carney complex (CC) is an autosomal dominant syndrome, characterized by multiple endocrine neoplasms, pigmented skin lesions, endocrine hyper-activity and myxomas. Case study: C. E., 71 years old, was addressed to our center in August 1994, following the finding of a sellar enlargement in a skull radiography performed after an accident. A pituitary tomography showed the presence of a lesion extended up to the optic chiasm, a macroadenoma that was treated with transsphenoidal endoscopic surgery. A histological diagnosis of a “GH secreting macroadenoma” was performed. An echocardiographic study highlighted an atrial isolated myxoma that was subsequently removed. A contrast-enhanced abdominal magnetic resonance imaging (MRI) excluded adrenal lesions. In 2001, in relation to relapse of Acromegaly, the patient started therapy with somatostatin analogues which was replaced, in 2008, by Pegvisomant to obtain biochemical control of the disease. Conclusions: At the time of initial screening, it is important not to underestimate the possibility that certain clinical features fall within the context of more complex syndromes. The knowledge of how Acromegaly presents itself in relation to CC and its associated characteristics such as cardiac myxoma or typical skin lesions, will help clinicians to timely diagnose this rare disease and treat it appropriately.
No takes yet. Share an insight, caveat, or question.
Costa et al. (2020) conducted a case report in Carney complex and Acromegaly (n=1). Transsphenoidal endoscopic surgery, myxoma removal, and medical therapy (somatostatin analogues, Pegvisomant) was evaluated. A 71-year-old patient with Carney complex achieved biochemical control of acromegaly using Pegvisomant after transsphenoidal surgery for a GH-secreting macroadenoma and removal of an atrial myxoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: